Eloxx Pharmaceuticals Overview
Eloxx Pharmaceuticals focuses on the discovery, development, and commercialization of compounds for the treatment of rare genetic diseases including cystic fibrosis, Duchenne muscular dystrophy, Usher syndrome, ataxia-telangiectasia, beta thalassemia, and Tay-Sachs Hurler syndrome. Its platform technologies are uniquely positioned to transform genetic diseases by correcting two defects, nonsense mutations implicated in many rare diseases and ribosomal mutations driving cancer. The companys approach allows it to move rapidly from a target drug-discovery program to clinical drug candidates. Eloxx Pharmaceuticals is building a pipeline of molecules designed for an array of genetic diseases caused by nonsense mutations. In June 2017, Eloxx Pharmaceuticals reverse-merged with Sevion Therapeutics Inc. This acquisition transitioned Eloxx from a private to a publicly traded company.
Cumulative Funding Raised Over Time ($)
$38.0MAug 2017
$46.5MNov 2013
Latest News
growth-positive
Eloxx Pharmaceuticals Announces Key Corporate Accomplishments
Eloxx Pharmaceuticals has announced promising results from its proof-of-concept trial for ELX-02, a treatment for Nonsense Mutation Alport Syndrome (NMAS). The trial demonstrated the production of collagen alpha 4 and alpha 5 proteins in patients, marking a significant milestone in the therapys development. These findings were presented at the ASN Kidney Week, highlighting the potential of ELX-02 to address this rare genetic disorder. The FDA has also allowed continued dosing in the Phase 1 trial of another treatment, ZKN-013, which is a notable achievement for Eloxx. The company is poised for further development and potential milestone payments from its partner, Almirall, pending confirmation. The event took place in late October 2024.
Partners
growth-positive
Eloxx Pharmaceuticals Provides Pipeline and Financing Updates
Eloxx Pharmaceuticals has announced significant updates regarding its pipeline and financing. The company has dosed the first two subjects in a Phase 1 clinical trial of ZKN-013, a drug being developed for the treatment of rare dermatological and other diseases. The company has also secured a binding commitment for an additional $3.2 million in financing to advance its clinical programs. Furthermore, the company has received positive feedback from the FDA regarding its IND application for a Phase 2 clinical trial in the US with ELX-02 in patients with nonsense mutation alport syndrome (NMAS).
InvestmentPartners
growth-positive
Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates
Eloxx Pharmaceuticals has been granted Orphan Drug Designation (ODD) by the U.S. FDA for the treatment of Alport Syndrome with its drug ELX-02. The company has also signed a global licensing partnership with Almirall Pharmaceuticals for ZKN-013, receiving a $3M upfront payment and up to $470M in milestones and tiered royalties on global sales. A recent paper published on Autosomal Dominant Polycystic Kidney Disease (ADPKD) shows that ELX-02 treatment prevents cyst formation in diseased PKD organoids with nonsense mutations and a single healthy gene copy.
PartnersInvestment
growth-positive
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases
Eloxx Pharmaceuticals and Almirall have entered into an exclusive license agreement for the development and commercialization of ZKN-013, a drug designed to treat rare dermatological diseases. Under the agreement, Almirall will have global rights to ZKN-013, which is expected to enter Phase I development soon. Eloxx will receive an upfront payment of $3 million, with potential additional payments throughout the development phases, including regulatory and sales milestones of up to $470 million. The partnership aligns with Almiralls R&D strategy to develop novel treatments for dermatological conditions, including rare diseases.
PartnersInvestment
growth-negative
Off the Beaten Path: 3 Delisted Stocks for The Speculative Investor
The article discusses the potential for recovery and growth in companies that have been delisted from major stock exchanges. It highlights three companies - Elys Game Technology, Enthusiast Gaming, and Eloxx Pharmaceuticals - that have recently been delisted but could potentially offer value to speculative investors. The companies have seen significant drops in their equity value and now trade on the over-the-counter market. However, the article suggests that these companies could rebound due to their relevance in growing industries such as sports gambling, video game journalism, and gene therapy.
Public Trading
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $98.5M |
| Last funding | $2M |
| Stage | Public |
| Rounds | 4 |
| Investors | 10 |
Team Members
2
Employees: 11-50
Web & Social Links
| Website | www.eloxxpharma.com |
| Careers | Careers page |
Locations
Ness Ziona, Israel
480 Arsenal Wy, Watertown, MA 02472, USA
Photos & Videos
1 item(s)
Eloxx Pharmaceuticals Business
Business models
B2B
Product stage
Released
Employees
11-50
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentTarget Customer
Healthcare & Life SciencesLife SciencesBiotechnologyPharmaceuticalsHealthcarePatientsCore Technology
BiologicalsMoleculesTags (9)
rare-diseasesdrug-discoverybiopharmaceuticalbiotechnologytherapeuticspharmaceuticalspharma-companiespatientsgenetic-disordersGeographic Markets
North AmericaEloxx Pharmaceuticals Financials
$98.5M
Total funding
Undisclosed
Capital raised
$2M
Last funding
Public
Funding stage
4
Total rounds
10
Investors
Cumulative Funding Raised Over Time ($)
$38.0MAug 2017
$46.5MNov 2013
Private Equity Funding
C Round
Aug 2017
$38M
Korea Investment Partners, Phil Frost, GF Securities, Catalyst, DSC Investment, OPKO Health, Quark Pharmaceuticals, LSP BioVentures, Samsung Catalyst Fund, Pontifax
A Round
Nov 2013
$8.5M
Pontifax
Public Offering / Exit
POEvent
Sep 2023
Undisclosed
POEvent
Apr 2018
Undisclosed
Mergers & Acquisitions
MNAEvent
Apr 2021
$7.6M
MNAEvent
Dec 2017
Undisclosed
Eloxx Pharmaceuticals Lifecycle
Cumulative Funding Raised Over Time
$38.0MAug 2017
$46.5MNov 2013
All Events
C Round
Aug 2017
$38M
Korea Investment Partners, Phil Frost, GF Securities, Catalyst, DSC Investment, OPKO Health, Quark Pharmaceuticals, LSP BioVentures, Samsung Catalyst Fund, Pontifax
A Round
Nov 2013
$8.5M
Pontifax
POEvent
Sep 2023
Undisclosed
POEvent
Apr 2018
Undisclosed
MNAEvent
Apr 2021
$7.6M
MNAEvent
Dec 2017
Undisclosed
Eloxx Pharmaceuticals News
55 articles
growth-positive
Eloxx Pharmaceuticals Announces Key Corporate Accomplishments
Eloxx Pharmaceuticals has announced promising results from its proof-of-concept trial for ELX-02, a treatment for Nonsense Mutation Alport Syndrome (NMAS). The trial demonstrated the production of collagen alpha 4 and alpha 5 proteins in patients, marking a significant milestone in the therapys development. These findings were presented at the ASN Kidney Week, highlighting the potential of ELX-02 to address this rare genetic disorder. The FDA has also allowed continued dosing in the Phase 1 trial of another treatment, ZKN-013, which is a notable achievement for Eloxx. The company is poised for further development and potential milestone payments from its partner, Almirall, pending confirmation. The event took place in late October 2024.
Partners
growth-positive
Eloxx Pharmaceuticals Provides Pipeline and Financing Updates
Eloxx Pharmaceuticals has announced significant updates regarding its pipeline and financing. The company has dosed the first two subjects in a Phase 1 clinical trial of ZKN-013, a drug being developed for the treatment of rare dermatological and other diseases. The company has also secured a binding commitment for an additional $3.2 million in financing to advance its clinical programs. Furthermore, the company has received positive feedback from the FDA regarding its IND application for a Phase 2 clinical trial in the US with ELX-02 in patients with nonsense mutation alport syndrome (NMAS).
InvestmentPartners
growth-positive
Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates
Eloxx Pharmaceuticals has been granted Orphan Drug Designation (ODD) by the U.S. FDA for the treatment of Alport Syndrome with its drug ELX-02. The company has also signed a global licensing partnership with Almirall Pharmaceuticals for ZKN-013, receiving a $3M upfront payment and up to $470M in milestones and tiered royalties on global sales. A recent paper published on Autosomal Dominant Polycystic Kidney Disease (ADPKD) shows that ELX-02 treatment prevents cyst formation in diseased PKD organoids with nonsense mutations and a single healthy gene copy.
PartnersInvestment
growth-positive
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases
Eloxx Pharmaceuticals and Almirall have entered into an exclusive license agreement for the development and commercialization of ZKN-013, a drug designed to treat rare dermatological diseases. Under the agreement, Almirall will have global rights to ZKN-013, which is expected to enter Phase I development soon. Eloxx will receive an upfront payment of $3 million, with potential additional payments throughout the development phases, including regulatory and sales milestones of up to $470 million. The partnership aligns with Almiralls R&D strategy to develop novel treatments for dermatological conditions, including rare diseases.
PartnersInvestment
growth-negative
Off the Beaten Path: 3 Delisted Stocks for The Speculative Investor
The article discusses the potential for recovery and growth in companies that have been delisted from major stock exchanges. It highlights three companies - Elys Game Technology, Enthusiast Gaming, and Eloxx Pharmaceuticals - that have recently been delisted but could potentially offer value to speculative investors. The companies have seen significant drops in their equity value and now trade on the over-the-counter market. However, the article suggests that these companies could rebound due to their relevance in growing industries such as sports gambling, video game journalism, and gene therapy.
Public Trading
growth-positive
Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update
Eloxx Pharmaceuticals, Inc. reported positive results from its Phase 2 clinical trial of ELX-02 for treating Alport Syndrome, showing significant improvement in kidney morphology and proteinuria in patients. The company presented these findings at the American Society of Nephrology Kidney Week 2023. Eloxx is also making significant progress towards a strategic partnership for ZKN-013 and has raised additional funds to strengthen its balance sheet. The trial demonstrated ELX-02s potential as a disease-modifying treatment, with improvements observed in podocyte foot process effacement and collagen protein expression. The treatment was well-tolerated, with no discontinuations. These developments indicate a positive trajectory for Eloxxs pipeline and strategic initiatives.
PartnersInvestment
growth-positive
Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update
Eloxx Pharmaceuticals has reported positive results from its Phase 2 clinical trial of ELX-02 for the treatment of Alport Syndrome. The trial showed improved kidney morphology in all three patients, with protein re-expression consistent with disease regression. The company also reported progress towards a strategic partnership for ZKN-013. Eloxx reported a net loss of $3.6 million for Q3 2023, compared to a net loss of $7.5 million for the same period in the previous year. The company raised additional cash to strengthen its balance sheet, and is focused on raising more capital in the near term.
InvestmentPartners
growth-positive
Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria
Eloxx Pharmaceuticals has reported positive results from a clinical trial of its ELX-02 treatment for Nonsense Mutation Alport syndrome, a rare kidney disease. The trial, conducted in partnership with NIPOKA GmbH, showed that the treatment improved kidney morphology in all three patients by an average of 60%. The results support the clinical benefit of the treatment and have led to recommendations for continued development. Eloxx Pharmaceuticals is a leader in ribosomal RNA-targeted genetic therapies for rare diseases.
CustomersInvestment
Growth-Positive
Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Eloxx Pharmaceuticals, Inc. has announced a definitive agreement for the issuance and sale of 380,590 of its shares of common stock at a purchase price of $5.255 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, Eloxx has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 380,590 of its shares of common stock. The gross proceeds to Eloxx from the offering are expected to be approximately $2 million. The offering is expected to close on or about September 20, 2023.
Investment
growth-positive
Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome
Eloxx Pharmaceuticals has reported positive results from its Phase 2 clinical trial of ELX-02 for the treatment of Alport syndrome, a rare genetic kidney disorder. The trial showed an improvement in foot process effacement in all three treated patients, indicating disease regression. The company now intends to gain alignment with the FDA on the design of a pivotal trial for ELX-02 and the potential for seeking Breakthrough Therapy Designation. Eloxx recently submitted an Investigational New Drug application to the FDA for ELX-02.
InvestmentExpand
Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome
growth-positive
Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013
Eloxx Pharmaceuticals has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for ELX-02, a treatment for Alport syndrome with nonsense mutations. The company has reported positive results from its Phase 2 clinical study evaluating ELX-02. The FDA has also approved the start of a Phase 1 single ascending dose (SAD) trial for ZKN-013. Eloxx has received significant strategic interest in ZKN-013, which the company is actively pursuing. The company is also focusing on fully maximizing the potential of ELX-02 in rare kidney diseases and continuing funded discovery efforts on its TURBO-ZM platform.
InvestmentExpand
growth-positive
Eloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome
Eloxx Pharmaceuticals has reported positive results from its Phase 2 clinical trial of ELX-02 for the treatment of Alport syndrome, a rare genetic kidney disorder. All three patients treated with ELX-02 showed an improvement in podocyte foot process effacement, a hallmark of Alport syndrome. The company intends to advance ELX-02 into a pivotal trial for the treatment of Alport syndrome with nonsense mutations. Eloxx Pharmaceuticals is a leader in ribosomal RNA-targeted genetic therapies for rare diseases.
InvestmentExpand
growth-positive
Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement
Eloxx Pharmaceuticals, a leader in ribosomal RNA-targeted genetic therapies for rare diseases, has been granted an extension by the Nasdaq Listing Qualifications Panel to regain compliance with Listing Rule 5550(b)(2). This rule requires a listed company to have at least $35 million in market value of listed securities to qualify for continued listing on the Nasdaq Capital Market. The extension, which follows a request submitted by Eloxx, will last until October 9, 2023. The company is currently working on a plan to regain compliance with Nasdaq’s minimum market value requirement.
Public Trading
growth-positive
Eloxx Pharmaceuticals Announces Publication Demonstrating the Power of its TURBO-ZM™ Platform to Target the Human Ribosome for Therapeutic Benefit
Eloxx Pharmaceuticals, Inc. has announced the publication of research demonstrating the potential of its TURBO-ZM chemistry technology platform to develop novel Ribosome Modulating Agents (RMAs) that can target MYC overexpressing cancers. The research, published in Cancer Research Communications, details preclinical data that demonstrate activity for ZKN-157 against subtypes of colorectal cancer. The company believes this opens up opportunities to selectively target MYC-driven cancers with a novel mechanism and has potential for synergy with existing cancer therapies.
InvestmentExpand
growth-positive
Eloxx Pharmaceuticals Key Opinion Leader Event Highlights Significant Unmet Need in Treatment of Alport Syndrome Patients with Nonsense Mutations and Additional Positive Results from Phase 2 Clinical Study Evaluating ELX-02
Eloxx Pharmaceuticals has announced additional results from its Phase 2 ELX-02 trial for the treatment of Alport syndrome, a rare progressive hereditary kidney disease. The patient who achieved remission rebounded one month after withdrawing treatment, providing further evidence of the drugs activity. The company intends to advance into a pivotal trial of ELX-02 for the treatment of Alport syndrome with nonsense mutations. The announcement was made during a key opinion leader event which discussed the significant unmet medical need of patients with Alport syndrome.
InvestmentExpand
growth-positive
Eloxx Pharmaceuticals Highlights Recent Alport Syndrome Natural History Data Presented at 60th ERA Congress
Eloxx Pharmaceuticals has announced that data from a natural history study supports its decision to advance into a pivotal trial in Alport syndrome with nonsense mutations. The study, presented at the 60th European Renal Association Congress, found that Alport syndrome patients with autosomal recessive COL4A4 mutations have the severest disease, with a more rapid progression to kidney failure. Eloxxs Chief Medical Officer was involved in the study. The companys lead investigational product candidate, ELX-02, is in Phase 2 clinical development for the treatment of Alport syndrome in patients with nonsense mutations.
InvestmentExpand
growth-positive
Eloxx Pharmaceuticals to Host Investor and Analyst Call on Alport Syndrome
Eloxx Pharmaceuticals will host an Investor and Analyst call to highlight the significant unmet need in the treatment of Alport syndrome. The call will provide additional data from the Phase 2 clinical trial, following the achievement of remission in one patient. The company has decided to advance into a pivotal trial for Alport syndrome. Alport syndrome is a genetic disorder characterized by kidney disease, hearing loss, and eye abnormalities. Eloxx Pharmaceuticals is a leader in ribosomal RNA-targeted genetic therapies for rare diseases.
Investment
growth-positive
Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) Patients
Eloxx Pharmaceuticals announced the final data assessment from the Phase 2 clinical trial of ELX-02 in combination with ivacaftor in Class 1 CF patients with at least one nonsense mutation. The trial results demonstrated a clinically relevant improvement in percent predicted forced expiratory volume (ppFEV1). The efficacy of ELX-02 in the CF study supports Eloxxs decision to advance into a pivotal trial in Alport syndrome. The Phase 2 trial of ELX-02 in Alport syndrome patients with nonsense mutations also showed promising results, with one patient experiencing remission. Eloxx believes that these results validate the disease-modifying potential of ELX-02. The company plans to further study ELX-02 in Alport syndrome, as the high concentrations of the drug observed in the kidney make it an ideal target for treatment.
Customers
growth-positive
Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement
Eloxx Pharmaceuticals has been granted an extension by the Nasdaq Hearings Panel to regain compliance with the Nasdaq Listing Rule. The company must achieve certain milestones included in a plan of compliance to qualify for continued listing on the Nasdaq Capital Market. Eloxx has made progress in advancing its pipeline of small molecule genetic therapies for rare genetic diseases. They have announced the decision to advance ELX-02 into a pivotal study in Alport Syndrome patients and received clearance from the FDA to start a Phase 1 study with ZKN-013. The company was notified by Nasdaq in October 2022 that it no longer complied with the Market Value of Listed Securities requirement, but the extension allows them until July 30, 2023, to regain compliance.
Public Trading
growth-positive
Atossa Appoints Life Sciences Financial and Operations Industry Veteran Greg Weaver as Chief Financial Officer
Atossa Therapeutics, Inc. has appointed Greg Weaver as its new Chief Financial Officer (CFO). Weaver brings over 30 years of experience in life sciences, finance, and operations to the company. He has previously served as CFO of BioIntelliSense and atai Life Sciences, where he led a successful IPO and raised over $500 million. Weaver has also held executive roles in several oncology-focused biotech companies. Atossa Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative medicines for breast cancer and other areas of unmet medical need in oncology.
Management Changes
growth-positive
Eloxx Pharmaceuticals Intends to Advance ELX-02 into Pivotal Trial for the Treatment of Alport Syndrome with Nonsense Mutations Following Achievement of Remission in Patient in Phase 2 Study
Eloxx Pharmaceuticals plans to advance ELX-02 into a pivotal trial for the treatment of Alport syndrome with nonsense mutations after achieving remission in one patient in its Phase 2 clinical study. The patient demonstrated a significant reduction in urine protein creatinine ratio (UPCR) from baseline. The company intends to discuss the findings with the FDA and aims to advance the program into a pivotal trial. Alport syndrome is a genetic disorder characterized by kidney disease, hearing loss, and eye abnormalities caused by mutations in certain genes. Eloxxs lead investigational product candidate, ELX-02, is a small molecule drug designed to restore production of full-length functional proteins.
Customers
growth-positive
Eloxx Pharmaceuticals Plans To Take ELX-02 Into Pivotal Trial For Alport Syndrome
Eloxx Pharmaceuticals plans to advance ELX-02 into a pivotal trial for treating Alport syndrome with nonsense mutations. One patient in their Phase 2 study achieved remission, demonstrating a significant reduction in urine protein creatinine ratio (UPCR) from baseline. ELX-02 was well tolerated in the trial. Eloxx intends to provide more detailed results at an upcoming medical meeting. The companys shares are down 5.12% at $8.15.
Customers
growth-positive
Eloxx Pharmaceuticals Reports First Quarter 2023 Financial and Operating Results and Provides Business Update
Eloxx Pharmaceuticals has reported its Q1 2023 financial results and provided a business update. The company has received FDA clearance to begin a single ascending dose clinical trial for ZKN-013 for the potential treatment of recessive Dystrophic Epidermolysis Bullosa. The company has also dosed three patients with ELX-02 in the ongoing proof-of-concept Phase 2 open-label clinical trial for Alport syndrome. The company incurred a net loss of $6.2 million for the three months ended March 31, 2023. As of March 31, 2023, the company had unrestricted cash and cash equivalents of $4.9 million.
Investment
growth-positive
Eloxx Pharmaceuticals Announces FDA Clearance to Begin Single Ascending Dose Study of ZKN-013
Eloxx Pharmaceuticals has received clearance from the U.S. Food and Drug Administration (FDA) to initiate a single ascending dose (SAD) clinical trial for ZKN-013, a potential treatment for recessive Dystrophic Epidermolysis Bullosa (RDEB) and Familial Adenomatous Polyposis (FAP). This is the first drug candidate from Eloxx’s TURBO-ZM™ platform to gain clearance for clinical testing. The company also has TURBO-ZM based discovery programs in cystic fibrosis and certain cMYC-overexpressing cancers.
InvestmentExpand
Eloxx Pharmaceuticals Reports Fourth Quarter 2022 Financial and Operating Results and Provides Business Update
Eloxx Pharmaceuticals Announces Submission of Investigational New Drug (IND) Application for ZKN-013
Eloxx Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
Eloxx Pharmaceuticals Announces Initiation of Phase 2 Clinical Study Evaluating ELX-02 for the Treatment of Alport Syndrome with First Patient Dosed
growth-positive
Eloxx Pharmaceuticals making progress on Phase 2 clinical study for ELX-02 Alport syndrome candidate
Eloxx Pharmaceuticals provides an update on the clinical study for its lead investigational product candidate ELX-02. The company has enrolled the first batch of patients in its Phase 2 study for the treatment of Alport syndrome in patients with nonsense mutations. The study will involve dosing up to eight patients for two months with a three-month follow-up. The company expects to deliver topline clinical results from this trial in the first half of 2023.
Customers
Eloxx Pharmaceuticals Announces First Patients Enrolled in Phase 2 Clinical Study Evaluating ELX-02 for the Treatment of Alport Syndrome
Eloxx Pharmaceuticals Announces Reverse Stock Split Effective
Eloxx Pharmaceuticals Reports Third Quarter 2022 Financial and Operating Results and Provides Business Update
growth-positive
Eloxx Pharmaceuticals Announces Opening of Clinical Trial Sites for Phase 2 Study of ELX-02 for the Treatment of Alport Syndrome
Eloxx Pharmaceuticals, a leader in ribosomal RNA-targeted genetic therapies for rare diseases, has announced the opening of clinical trial sites for its Phase 2 study of ELX-02 for the treatment of Alport syndrome in patients with nonsense mutations. The clinical trial will include up to eight Alport syndrome patients with nonsense mutations in the second half of 2022. Topline results are expected in the first half of 2023. Eloxx believes there is a strong rationale to pursue clinical development of ELX-02 in Alport syndrome, based on encouraging preclinical results.
Expand
Eloxx (ELOX) Down After Cystic Fibrosis Study Fails to Meet Goal
growth-negative
Eloxx Pharmaceuticals Reports Topline Results from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) Patients
Eloxx Pharmaceuticals announced topline results from the Phase 2 clinical trial of ELX-02 in combination with ivacaftor in Class 1 cystic fibrosis (CF) patients. The combination trial did not achieve statistical significance for efficacy endpoints. ELX-02 was well tolerated but did not show incremental improvement when combined with ivacaftor. The trial results were potentially confounded by high variability in sweat chloride and lung function measurement. Eloxx will work with the CF Foundation to determine the next steps in the development of ELX-02 for CF. Despite the setback, Eloxx plans to initiate a proof-of-concept trial for ELX-02 in Alport syndrome later this year.
Customers
Eloxx Pharmaceuticals Reports Topline Results from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) Patients
Eloxx Pharmaceuticals Reports Second Quarter 2022 Financial and Operating Results and Provides Business Update
growth-positive
Eloxx Pharmaceuticals Announces Changes to Board of Directors
Eloxx Pharmaceuticals has appointed Lindsay Androski to its board of directors. Androski brings significant experience in growing biotech companies and will contribute to Eloxxs work in developing therapies for rare diseases. Several current board members have stepped down. The changes in the board composition support the companys transformation and acquisition of Zikani. Eloxx Pharmaceuticals is engaged in the science of ribosome modulation and is developing novel Ribosome Modulating Agents (RMAs) and Eukaryotic Ribosome Selective Glycosides (ERSGs). Their lead investigational product candidate, ELX-02, is in clinical development for the treatment of cystic fibrosis.
Management Changes
Eloxx Pharmaceuticals Announces Changes to Board of Directors
growth-positive
Eloxx Pharmaceuticals Announces New Development Program for ELX-02 for the Treatment of Alport Syndrome
Eloxx Pharmaceuticals has announced the expansion of its ELX-02 development program to include the treatment of Alport syndrome, a rare kidney disease. The company plans to initiate clinical testing of ELX-02 in Alport syndrome in the second half of 2022, with topline results expected in the first half of 2023. Eloxx believes there is a strong rationale to pursue clinical development of ELX-02 in Alport syndrome, based on encouraging preclinical results. The company intends to initiate a proof-of-concept clinical trial in up to eight Alport syndrome patients with nonsense mutations in the second half of 2022.
Expand
Growth-Positive
Eloxx Pharmaceuticals Announces Therapeutic Development Award from Cystic Fibrosis Foundation
Eloxx Pharmaceuticals has received a Therapeutic Development Award of up to $15.9 million from the Cystic Fibrosis Foundation to support the ongoing ELX-02 clinical program. This funding is in addition to the previously announced partial funding of the global clinical trial program. The funding will be tranched based on the achievement of certain clinical milestones. Eloxx will pay the CF Foundation royalties tiered to the actual level of funding from the CF Foundation. The additional award extends Eloxxs cash runway into the second quarter of 2023.
Investment
growth-positive
Eloxx Pharmaceuticals Acquires Zikani Therapeutics
Eloxx Pharmaceuticals, Inc. has acquired Zikani Therapeutics, Inc. in an all-stock transaction. The acquisition is expected to create a leader in ribosomal RNA-targeted therapies for the treatment of rare diseases and oncology. Sumit Aggarwal, previously the President and CEO of Zikani, has been named President and CEO of Eloxx. The acquisition will help to amplify the potential of Eloxxs innovative science by developing a new class of therapies to treat diseases with limited to no treatment options. The combined capabilities of Eloxx and Zikani will further accelerate the ability to impact the lives of those who have rare diseases.
AcquisitionManagement Changes
growth-positive
Eloxx Pharmaceuticals Receives U.S. Orphan Drug Designation for ELX-02 for the Treatment of Cystic Fibrosis
Eloxx Pharmaceuticals has received orphan drug designation from the FDA for ELX-02 for the treatment of Cystic Fibrosis. This designation grants Eloxx certain benefits, including market exclusivity, exemption of FDA application fees, tax credits, and eligibility for grant funding opportunities. The company has also received orphan medicinal product designation from the European Medicines Agency. Eloxx is currently conducting Phase 2 proof of concept clinical trials for ELX-02. The trial in the U.S. is temporarily paused due to the COVID-19 pandemic. Eloxx aims to provide treatment options for patients with high unmet medical needs, particularly those with nonsense mutations. The company is focused on developing RNA-modulating drug candidates to treat rare and ultra-rare premature stop codon diseases.
Customers
growth-positive
Eloxx Pharmaceuticals Presents New Positive Data for ELX-02 at the American Society of Nephrology (ASN) Kidney Week 2019
Eloxx Pharmaceuticals announced new data from two abstracts presented at the American Society of Nephrology (ASN) Kidney Week 2019. The results of their renal impairment study support the expansion of their research in the kidney beyond nephropathic cystinosis into other areas such as autosomal dominant polycystic kidney disease. The data also support the future evaluation of ELX-02 in Phase 2 trials with nonsense mediated diseases. Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cystic fibrosis, cystinosis, inherited retinal disorders, and other diseases caused by nonsense mutations limiting production of functional proteins.
Expand
growth-positive
Eloxx Pharmaceuticals to Present at the 8th Annual SVB Leerink Global Healthcare Conference in New York City on Friday, March 1, 2019
Eloxx Pharmaceuticals, a clinical-stage biopharmaceutical company, announced that its Chairman and CEO will make a company presentation and host one-on-one meetings with investors at the 8th Annual SVB Leerink Healthcare Conference. The presentation will focus on the companys novel RNA-modulating drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. Eloxxs lead investigational product candidate, ELX-02, is in the early stages of clinical development for cystic fibrosis and cystinosis. The company is also developing a new program for rare ocular genetic disorders. Eloxx Pharmaceuticals is dedicated to the discovery and development of therapeutics for various genetic diseases caused by nonsense mutations.
Investment
growth-positive
Eloxx Pharmaceuticals to Present at the 2019 BIO CEO and Investor Conference in New York City on Monday, February 11, 2019
Eloxx Pharmaceuticals announced that its CEO will make a company presentation and host one-on-one meetings with investors at the 2019 BIO CEO and Investor Conference. Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel RNA-modulating drug candidates to treat rare and ultra-rare premature stop codon diseases. Their lead investigational product candidate is ELX-02, a small molecule drug candidate designed to restore production of full-length functional proteins. Eloxx is dedicated to the discovery and development of therapeutics for cystic fibrosis, cystinosis, inherited retinal disorders, and other diseases caused by nonsense mutations.
Investment
growth-positive
Eloxx Pharmaceuticals raises $50m on Nasdaq
Eloxx Pharmaceuticals has raised $50 million in a financing round and will be listed on Nasdaq. The company, which develops drugs for rare genetic diseases, is focused on developing a drug for the treatment of cystic fibrosis. Eloxxs share price has risen 30% this year, and its market cap before the current round was $279 million. The company plans to begin Phase II clinical trials for its cystic fibrosis drug and Phase II trials for a drug to treat cystinosis. Eloxx was previously controlled by former Teva Pharmaceutical Industries chairperson Phillip Frost and merged with a stock exchange shell listed on the over-the-counter index in the US. Other shareholders include Pontifax Venture Capital and Gilad Shabtai.
InvestmentManagement Changes
growth-positive
Biotech Company Eloxx Wants to Raise $50 Million on Nasdaq
Biotech company Eloxx Pharmaceuticals Inc. is conducting an underwritten public offering of its ordinary shares on Nasdaq, expecting to raise $50 million. The offering is pursuant to its shelf registration statement and marks Eloxxs transition from the over-the-counter securities market to Nasdaq. Eloxx is a clinical-stage company developing gene-modulating drug candidates for rare premature stop codon diseases, including cystic fibrosis. The company was formed through a merger between Sevion Therapeutics, Inc. and Eloxx Pharmaceuticals Ltd. Eloxx plans to use the proceeds for research and development and general corporate purposes.
Public Trading
growth-positive
Eloxx Pharmaceuticals Secures US$8 Million Investment from LSP, Increasing Total Raised in Series C to US$38 million
Eloxx Pharmaceuticals has closed an additional $8 million investment led by LSP, bringing the total Series C financing raised to $38 million. The investment will be used to advance Eloxxs lead product candidate, ELX-02, into multiple Phase 2 studies. Eloxx is also planning to initiate clinical studies for ELX-02 in cystic fibrosis and cystinosis patients. In addition, Eloxx has signed a definitive agreement for an acquisition transaction with Sevion Therapeutics, under which Eloxx will become a wholly owned subsidiary of Sevion. Upon completion of the transaction, Sevion will change its name to Eloxx Pharmaceuticals, Inc. and intends to have its shares listed for trading on NASDAQ.
InvestmentAcquisitionPublic Trading
growth-positive
Eloxx Pharmaceuticals Raises US$6M in Funding - FinSMEs
Eloxx Pharmaceuticals has raised an additional $6 million in Series C funding, bringing the total amount raised in the round to $30 million. The funding round was led by Dr. Phil Frost, OPKO Health Inc., and Pontifax. This funding is part of the acquisition agreement between Sevion Therapeutics and Eloxx Pharmaceuticals, where Eloxx will become a wholly owned subsidiary of Sevion. Upon completion of the transaction, Sevion will change its name to Eloxx Pharmaceuticals, Inc. and intends to have its shares listed for trading on NASDAQ. Eloxx Pharmaceuticals is a clinical stage company developing therapeutics for genetic diseases caused by nonsense mutations.
InvestmentAcquisitionPublic Trading
growth-positive
Eloxx Pharmaceuticals Raises US$24m in Series C Funding - FinSMEs
Eloxx Pharmaceuticals has raised US$24m in Series C funding. The funding will be used to expand the companys development efforts. Eloxx is developing ELX-02, a compound that has the potential to be the first disease-modifying therapy for genetic diseases caused by non-sense mutations. The compound has shown positive effects in animal models of various genetic diseases.
Investment
http://www.marketwired.com/press-release/eloxx-pharmacueticals-receives-a-us5-million-investment-from-quark-venture-gf-securities-2220964.htm
Sevion Therapeutics Inc. and Eloxx Pharmaceuticals Ltd Announce the Entering into of an Acquisition Transaction
growth-positive
Eloxx Pharmaceuticals, Ltd. Announced the Initial Closing of its First Round of Financing
Eloxx Pharmaceuticals has announced the initial closing of its first round of financing with Roche and Pontifax. The company is focused on the discovery, development, and commercialization of compounds for the treatment of genetic diseases caused by nonsense mutations. Eloxx has in-licensed a library of compounds developed by Prof. Timor Bassov from the Technion, which have shown excellent safety and efficacy in pre-clinical data. The company aims to develop a pipeline of small-molecule therapeutics that target genetic mutations caused by nonsense mutations. The technology developed by Prof. Bassov enables selective and safe ribosomal readthrough of premature termination codons. This financing round will support the companys efforts to bring novel therapeutic small molecules to patients suffering from genetic diseases.
Investment
Eloxx Pharmaceuticals Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 12 |
| Team members | 2 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 11 classification IDs that could be used for matching.
Eloxx Pharmaceuticals Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 90/100 |
| Missing | markets, not claimed |
| BI Verification | Sharon Shapira |
| Registrar ID | 514970706 |
| Crunchbase | eloxx |
| Creator | Rebecca Mack |
| Creator email | rebeccamack26@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2023-10-12T00:00:00.000Z |
| Created | 2014-07-27T00:00:00.000Z |
| Status detail | Public on NASDAQ on Apr, 2018<br> |